menu
    • menu
    [{"orgOrder":0,"company":"UMass Dartmouth","sponsor":"CaaMTech","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Expanded Collaboration","leadProduct":"Tryptamine","moa":"5-HT2A receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Discovery","graph3":"UMass Dartmouth","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"","sponsorNew":"UMass Dartmouth \/ CaaMTech","highestDevelopmentStatusID":"2","companyTruncated":"UMass Dartmouth \/ CaaMTech"},{"orgOrder":0,"company":"Mydecine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tryptamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Mydecine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"Mydecine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Mydecine \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Tryptamine

    Menu

    Tryptamine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mydecine

                            Canada arrow
                            BePharma
                            Not Confirmed

                            Mydecine

                            Canada arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tryptamine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mydecine Selects Substance Use Disorder and Smoking Cessation for Novel Psychedelic Molecule MYCO-004

                            Details : MYCO-004 is a patch-delivered tryptamine compound. Its properties include short duration (~2hours), transdermal, precision dosing and long-term compound stability.

                            Product Name : MYCO-004

                            Product Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 24, 2021

                            Lead Product(s) : Tryptamine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Undisclosed

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            UMass Dartmouth

                            Country arrow
                            BePharma
                            Not Confirmed

                            UMass Dartmouth

                            Country arrow
                            BePharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tryptamine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Discovery

                            Sponsor : CaaMTech

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            DEALS_DEV arrow-down

                            CaaMTech Expands Successful Next-Gen Drug Research Collaboration with UMass Dartmouth

                            Details : The renewal and expansion of this collaboration recognizes the success of Associate Professor of Chemistry & Biochemistry Dr. David R. Manke and his associated team of researchers in the synthesis and crystallography of novel tryptamines.

                            Product Name : Undisclosed

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 09, 2020

                            Lead Product(s) : Tryptamine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Discovery

                            Sponsor : CaaMTech

                            Deal Size : Undisclosed

                            Deal Type : Expanded Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth